Clicky

Calliditas Therapeutics AB(CALT)

Description: Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.


Keywords: Pharmaceutical Pharmaceutical Products Medication Pharmacy Health Sciences Kidney Disease Renal Disease Pharmaceutics Iga Nephropathy Nefecon

Home Page: www.calliditas.se

CALT Technical Analysis

Kungsbron 1, D5
Stockholm, 111 22
Sweden
Phone: 46 84 11 30 05


Officers

Name Title
Ms. Renee Aguiar-Lucander Chief Exec. Officer
Mr. Fredrik Johansson Chief Financial Officer
Dr. Katayoun Welin-Berger Ph.D. VP of Operations
Dr. Johan Haggblad Ph.D. Chief Scientific Officer
Mr. Mikael Widell Head of Communications & IR
Mr. Jonathan A. Schur Group Gen. Counsel
Ms. Sandra Frithiof Head of HR
Ms. Ann-Kristin Myde BSc Head of Clinical Devel. & VP of Project Management
Mr. Andrew B. Udell B.Sc., M.B.A. Pres of North America Commercial
Dr. Krassimir Mitchev Head of Medical Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 8.7719
Trailing PE: 0
Price-to-Book MRQ: 7.3857
Price-to-Sales TTM: 13.2379
IPO Date: 2020-06-05
Fiscal Year End: December
Full Time Employees: 98
Back to stocks